AbsEn.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Covid (26 mars) - Exploration (Accueil)

Index « AbsEn.i » - entrée « inhibitors »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
inhibitor < inhibitors < inhibitory  Facettes :

List of bibliographic references indexed by inhibitors

Number of relevant bibliographic references: 62.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000048 (2020) H. Li [République populaire de Chine] ; Y M Wang [République populaire de Chine] ; J Y Xu [République populaire de Chine] ; B. Cao [République populaire de Chine][Potential antiviral therapeutics for 2019 Novel Coronavirus].
000060 (2020) M L Sun [République populaire de Chine] ; J M Yang [République populaire de Chine] ; Y P Sun [République populaire de Chine] ; G H Su [République populaire de Chine][Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
000184 (2020) Joseph Thomas Ortega [États-Unis] ; Maria Luisa Serrano [Venezuela] ; Flor Helene Pujol [Venezuela] ; Hector Rafael Rangel [Venezuela]Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target
000363 (2020) Gabriela M. Kuster [Suisse] ; Otmar Pfister [Suisse] ; Thilo Burkard [Suisse] ; Qian Zhou [Suisse] ; Raphael Twerenbold [Suisse] ; Philip Haaf [Suisse] ; Andreas F. Widmer [Suisse] ; Stefan Osswald [Suisse]SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?
000421 (2020) Anh-Tien Ton [Canada] ; Francesco Gentile [Canada] ; Michael Hsing [Canada] ; Fuqiang Ban [Canada] ; Artem Cherkasov [Canada]Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.
000469 (2020) Yu Wai Chen [Hong Kong] ; Chin-Pang Bennu Yiu [Hong Kong] ; Kwok-Yin Wong [Hong Kong]Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates
000564 (2020) Mirko Baglivo [Italie] ; Manuela Baronio [Italie] ; Giuseppe Natalini [Italie] ; Tommaso Beccari [Italie] ; Pietro Chiurazzi [Italie] ; Ezio Fulcheri [Italie] ; Paolo Pietro Petralia [Italie] ; Sandro Michelini [Italie] ; Giovanni Fiorentini [Italie] ; Giacinto Abele Miggiano [Italie] ; Assunta Morresi [Italie] ; Gerolamo Tonini [Italie] ; Matteo Bertelli [Italie]Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?
000682 (2020) James H. Diaz [États-Unis]Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
000706 (2020) Shweta Saraswat ; Meenakshi Chaudhary ; Deepak SehgalHepatitis E Virus Cysteine Protease Has Papain Like Properties Validated by in silico Modeling and Cell-Free Inhibition Assays
000825 (2020) Hongzhou Lu [République populaire de Chine]Drug treatment options for the 2019-new coronavirus (2019-nCoV).
000854 (2020) Linlin Zhang [Allemagne] ; Daizong Lin [Allemagne] ; Xinyuanyuan Sun [Allemagne] ; Ute Curth [Allemagne] ; Christian Drosten [Allemagne] ; Lucie Sauerhering [Allemagne] ; Stephan Becker [Allemagne] ; Katharina Rox [Allemagne] ; Rolf Hilgenfeld [Allemagne]Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.
000857 (2020) Yaseen M. Arabi [Arabie saoudite] ; Robert Fowler [Canada] ; Frederick G. Hayden [États-Unis]Critical care management of adults with community-acquired severe respiratory viral infection
000979 (2020) Miguel Angel Martinez [Espagne]Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
000A45 (2020) Wanbo Tai [États-Unis] ; Lei He [République populaire de Chine] ; Xiujuan Zhang [États-Unis] ; Jing Pu [États-Unis, République populaire de Chine] ; Denis Voronin [États-Unis] ; Shibo Jiang [États-Unis, République populaire de Chine] ; Yusen Zhou [République populaire de Chine] ; Lanying Du [États-Unis]Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
000A92 (2020) George ThomsonCOVID-19: social distancing, ACE 2 receptors, protease inhibitors and beyond?
000B77 (2020) Ankit B. Patel [États-Unis] ; Ashish Verma [États-Unis]COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
000C25 (2020) Abdo A. ElfikyAnti-HCV, nucleotide inhibitors, repurposing against COVID-19
000D29 (2019) Kalkena Sivanesam ; Niels AndersenPre-structured hydrophobic peptide β-strands: A universal amyloid trap?
000D32 (2019) Belén Martínez-Gualda [Espagne] ; Liang Sun [Belgique] ; Olaia Martí-Marí [Espagne] ; Carmen Mirabelli [Belgique] ; Leen Delang [Belgique] ; Johan Neyts [Belgique] ; Dominique Schols [Belgique] ; María-José Camarasa [Espagne] ; Ana San-Félix [Espagne]Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum.
000F32 (2017) Ali A. Rabaan ; Shamsah H. Alahmed ; Ali M. Bazzi ; Hatem M. AlhaniA review of candidate therapies for Middle East respiratory syndrome from a molecular perspective
000F35 (2017) Ujjini H. Manjunatha ; Sumiti Vinayak [États-Unis] ; Jennifer A. Zambriski [États-Unis] ; Alexander T. Chao ; Tracy Sy [États-Unis] ; Christian G. Noble ; Ghislain M. C. Bonamy ; Ravinder R. Kondreddi ; Bin Zou ; Peter Gedeck ; Carrie F. Brooks [États-Unis] ; Gillian T. Herbert [États-Unis] ; Adam Sateriale [États-Unis] ; Jayesh Tandel [États-Unis] ; Susan Noh [États-Unis] ; Suresh B. Lakshminarayana ; Siau H. Lim ; Laura B. Goodman [États-Unis] ; Christophe Bodenreider ; Gu Feng ; Lijun Zhang [République populaire de Chine] ; Francesca Blasco ; Juergen Wagner ; F. Joel Leong ; Boris Striepen [États-Unis] ; Thierry T. DiaganaA Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "inhibitors" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "inhibitors" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV2
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    inhibitors
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Sat Mar 28 17:51:24 2020. Site generation: Sun Jan 31 15:35:48 2021